After identifying a proprietary cannabinoid profile, CRX-102, that demonstrates a profound and consistent effect on sleep disorders, CIT tested it using an animal model based on a standard dose of diazepam (10 mg) as control. From these studies, it was found that CRX-102 is capable of generating a similar response rate and predictable onset of sleep to diazepam.
Furthermore, it demonstrated a statistically significant longer duration of sleep than and there were fewer episodes of awakening and no apparent ‘hangover effect’ upon waking.
“The effects of CRX-102 are so consistent and pronounced that one can rarely measure similar robustness of results using other investigational small molecules,” stated Dr Shimon Lecht, R&D manager of CannRx and Ci Therapeutics.
The new anti-insomnia product, which is expected to launch in 2018, is the first GMP, pharmaceutical grade cannabis product available for adult patients suffering from sleep disorders.
“Insomnia is a serious and widespread medical problem. Using pharmaceutical level standards of analysis and clinical testing, CannRx is developing the next generation of cannabis products that are supported by quality science, robust clinical data and a strong safety profile,” added Dr Bill Levine, the executive chairman of CannRx Technologies. “Using the breakthrough CannRx technology that can be used to rapidly induce sleep with a prolonged ‘through the night’ therapeutic effect will be of great benefit to this population. We are excited about the opportunity to work together with iCAN team and launch the ican.sleep product.”